BPS Compounded Sterile Preparations Pharmacy Certification Examination Practice Test
Compounded sterile preparation practice involves controlling contamination and delivering the intended formulation, concentration, and route-specific characteristics. The BCSCP practice material addresses aseptic processing, component traceability, environmental monitoring, and quality investigations, alongside considerations such as excipient suitability and compatibility with infusion devices. These concepts connect preparation technique with patient safety and reliable sterile-product handling.
Exam overview
About the BPS Compounded Sterile Preparations Pharmacy Certification Examination Exam
Sterile compounding work requires linking process controls to product quality. Aseptic processing qualification uses media-fill simulations to assess whether personnel and procedures can maintain sterile conditions during representative manipulations. Environmental monitoring results need investigation in context, while analytical testing can help distinguish preparation errors from other causes of an unexpected concentration. Accurate records support traceability when materials move between containers, and findings that a component was out of specification call for prompt evaluation of potentially affected preparations. Formulation decisions also depend on the intended route: intrathecal products warrant attention to route-relevant properties, and excipients such as surfactants require suitability assessment. For hazardous drugs, engineering and work-practice controls reduce occupational exposure. Product release decisions may also require checking patient allergies, drug stability, and compatibility with the infusion device and administration system.
Sample Practice Questions
Review a selection from this exam's published US Practice Tests practice bank.
A pharmacy is preparing a sterile solution that will be administered intrathecally. Which formulation property warrants particular attention because of the administration route?
Show answer
Correct answer: AIntrathecal administration places a preparation directly into the central nervous system, so route-specific requirements include stringent sterility and control of bacterial endotoxins. Preservatives and other excipients should not be assumed suitable for this route, and tonicity and pH require appropriate formulation assessment.
A pharmacy is evaluating a proposed sterile formulation that contains a surfactant. Which concern is most relevant to its use?
Show answer
Correct answer: AExcipients such as surfactants must be justified for the formulation and assessed for compatibility and route-specific safety. They do not provide sterility assurance or replace other formulation and packaging controls.
A sterile preparation is found to have a concentration substantially different from its intended value during an investigation. Which analytical approach can help determine whether the error arose from the preparation process?
Show answer
Correct answer: AA suitable quantitative assay can assess drug concentration, provided the method and sampling approach are appropriate for the formulation. Visual appearance and gross weight do not directly establish concentration and may not detect a preparation error.
A pharmacy is reviewing an unexpected increase in environmental monitoring results. Which action best supports a useful investigation?
Show answer
Correct answer: AAn effective investigation evaluates the pattern and context of results, including cleaning, facility conditions, maintenance, and personnel practices. Repeat sampling may add information but should not replace review of the original findings.
A sterile preparation is being transferred between containers during compounding. Which practice best supports accurate traceability of the materials used?
Show answer
Correct answer: AA complete batch record links the finished preparation to the materials and process used, supporting investigation, recall, and quality review. Recording only container size or documenting only failures does not provide adequate traceability.
A pharmacy identifies that a preparation was made using a component later found to be out of specification. What should the pharmacy do first regarding potentially affected preparations?
Show answer
Correct answer: APrompt identification and quarantine of potentially affected preparations helps prevent further use while the scope and patient risk are assessed. Records should support tracing all batches that used the component.
When preparing a hazardous sterile drug, which measure is most directly intended to reduce occupational exposure during compounding?
Show answer
Correct answer: AHazardous drugs require risk-appropriate containment engineering controls and work practices to limit exposure, along with required personal protective equipment. Product sterility alone does not address worker safety.
How to use this practice test
The free US Practice Tests practice session draws up to 20 random questions from the 50-question BCSCP bank. Use the scenarios to practice applying sterile-compounding concepts to preparation, investigation, and release decisions. Results appear after the session, so review missed items by identifying the process control, formulation property, or compatibility issue that should guide the decision.
Preparation tips
- For intrathecal formulations, identify which product properties must be assessed in light of the administration route rather than assuming all sterile products share the same criteria.
- Practice tracing components through transfers between containers, and determine what records help identify preparations potentially affected by an out-of-specification component.
- Compare the purpose of media-fill qualification, environmental monitoring, and analytical testing; connect each method to the type of process or product question it can address.
- For hazardous sterile drugs, distinguish controls intended to protect the worker from controls intended to preserve product sterility.
- Work through release scenarios that combine excipient allergy, drug stability, and infusion-device compatibility rather than evaluating each factor in isolation.